Morphic Holding Analyst Ratings
Stifel Maintains Hold on Morphic Holding, Raises Price Target to $57
Stifel Maintains Morphic(MORF.US) With Hold Rating, Raises Target Price to $57
Stifel Nicolaus Keeps Their Hold Rating on Morphic Holding (MORF)
Jefferies Downgrades Morphic Holding to Hold From Buy, Price Target Is $57
Morphic Holding Buy Rating: High Acquisition Premium and Strategic Fit for Eli Lilly
RBC Capital downgraded Morphic's rating and target price.
Bank rating | Goldman Sachs: Eli Lilly's acquisition of Morphic has strategic significance with a target price of $793.
Morphic Holding Analyst Ratings
RBC Capital Downgrades Morphic Holding to Sector Perform, Lowers Price Target to $57
Morphic Holding Acquisition Prospects: A Balanced Hold Rating Amid Lilly's Offer and Pipeline Potential
Morphic Holding (MORF) Was Downgraded to a Hold Rating at RBC Capital
Analysts Conflicted on These Healthcare Names: HilleVax, Inc (HLVX), UnitedHealth (UNH) and Morphic Holding (MORF)
Favorable Outlook for Eli Lilly's Acquisition of Morphic Holding With Strong Prospects for MORF-057
Morphic Holding (MORF) Was Downgraded to a Hold Rating at TD Cowen
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Accolade (ACCD) and Morphic Holding (MORF)
Stifel Nicolaus Remains a Hold on Morphic Holding (MORF)
Morphic Holding (MORF) Gets a Buy From RBC Capital
Morphic Holding's Buy Rating Affirmed: Promising Trials and Strong Financial Outlook
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Morphic Holding (MORF)